MedinCell announces the great success of its capital increase and raises 15.6 M€

Strong demand enabling the contemplated size of the transaction to be significantly increased from 11 M€ to 15.6 M€ (+42%)

Major support from French and international shareholders and investors

Additional resources to finance the development of the product portfolio based on BEPO® technology combined with already approved and widely used active ingredients

Increased financial flexibility enabling the Company to achieve its strategic objectives and cover its working capital requirements until the second half of 2022 ; at this time MedinCell should already be receiving royalty revenues from the sale of the first products based on the BEPO® technology